These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28972047)

  • 1. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
    Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
    Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
    Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
    Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
    Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
    Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
    Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
    Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
    Leonard B; Starrett GJ; Maurer MJ; Oberg AL; Van Bockstal M; Van Dorpe J; De Wever O; Helleman J; Sieuwerts AM; Berns EM; Martens JW; Anderson BD; Brown WL; Kalli KR; Kaufmann SH; Harris RS
    Clin Cancer Res; 2016 Sep; 22(18):4746-55. PubMed ID: 27016308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GATA3 as a regulator for naughty cancer-associated fibroblasts in the microenvironment of high-grade serous ovarian cancer.
    El-Arabey AA; Abdalla M
    Hum Cell; 2021 Nov; 34(6):1934-1936. PubMed ID: 34432264
    [No Abstract]   [Full Text] [Related]  

  • 7. Expression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.
    Ganapathi MK; Jones WD; Sehouli J; Michener CM; Braicu IE; Norris EJ; Biscotti CV; Vaziri SA; Ganapathi RN
    Int J Cancer; 2016 Feb; 138(3):679-88. PubMed ID: 26311224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
    Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
    Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
    Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
    [No Abstract]   [Full Text] [Related]  

  • 11. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
    Gottlieb CE; Mills AM; Cross JV; Ring KL
    Gynecol Oncol; 2017 Mar; 144(3):607-612. PubMed ID: 28065619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
    Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.
    Peters PN; Whitaker RS; Lim F; Russell S; Bloom EA; Pollara J; Strickland KC; Cantwell MJ; Beg A; Berchuck A; Antonia S; Previs RA
    Neoplasia; 2024 Nov; 57():101056. PubMed ID: 39276533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.
    Feigenberg T; Clarke B; Virtanen C; Plotkin A; Letarte M; Rosen B; Bernardini MQ; Kollara A; Brown TJ; Murphy KJ
    Biomed Res Int; 2014; 2014():367103. PubMed ID: 24982872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
    K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
    Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
    Barlin JN; Jelinic P; Olvera N; Bogomolniy F; Bisogna M; Dao F; Barakat RR; Chi DS; Levine DA
    Gynecol Oncol; 2013 Mar; 128(3):512-7. PubMed ID: 23168173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
    Jiménez-Sánchez A; Cybulska P; Mager KL; Koplev S; Cast O; Couturier DL; Memon D; Selenica P; Nikolovski I; Mazaheri Y; Bykov Y; Geyer FC; Macintyre G; Gavarró LM; Drews RM; Gill MB; Papanastasiou AD; Sosa RE; Soslow RA; Walther T; Shen R; Chi DS; Park KJ; Hollmann T; Reis-Filho JS; Markowetz F; Beltrao P; Vargas HA; Zamarin D; Brenton JD; Snyder A; Weigelt B; Sala E; Miller ML
    Nat Genet; 2020 Jun; 52(6):582-593. PubMed ID: 32483290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
    Arend RC; Londoño AI; Montgomery AM; Smith HJ; Dobbin ZC; Katre AA; Martinez A; Yang ES; Alvarez RD; Huh WK; Bevis KS; Straughn JM; Estes JM; Novak L; Crossman DK; Cooper SJ; Landen CN; Leath CA
    Mol Cancer Res; 2018 May; 16(5):813-824. PubMed ID: 29523763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
    Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
    Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.